Hints and tips:
...Eyal Desheh told the Financial Times that it would be “a good idea” to include external directors with “an international pharmaceuticals background” as part of a “natural rotation” on the board....
...It swiftly appointed Eyal Desheh, the financial director, as interim chief executive and began a hunt for a replacement....
...Mr Vigodman will on February 11 take over from acting chief executive Eyal Desheh, who has been running the company since former CEO Jeremy Levin was sacked last year....
...Eyal Desheh, the chief financial officer, has been appointed as interim head....
...Mr Vigodman, who will take over from acting chief executive Eyal Desheh on February 11, said: “I understand the challenges facing Teva and I am confident that, together with the management team, we can ....
...Teva said it was appointing Eyal Desheh, executive vice-president and chief financial officer, to replace Mr Levin temporarily while searching for a replacement....
...They may yet end up picking a Teva insider, such as Eyal Desheh, the chief financial officer currently left in charge, or Erez Vigodman, who sits on the board. If so, boardroom relations will improve....
...Eyal Desheh, Teva’s chief financial officer, insisted Mr Yanai had made the decision himself to step down to pursue other unspecified “public activities”....
International Edition